Precision Value & Health recently surveyed 25 key decision makers at leading health plans and delivery networks regarding gene therapy—including who should be treated and when. STAT shares the intriguing results in this article by Jeremy Shafer, Senior VP of Access Experience, Precision for Value. Hint: cost isn’t the only answer.
There are many ways to assess cost—yet as new evidence surfaces about a therapy’s efficacy, original cost assessments may not change. Larry Blandford, Executive VP, Customer Solutions, Precision Value & Health, believes evolving the current assessment model is essential: To address concerns about soaring healthcare cost, focus on value.
Careful planning, improving access to care, and managing pain, depression and side effects are logical paths to better oncology care. Three Precision for Value experts—Larry Blandford, Executive Vice President, Managing Partner; Maureen Hennessey, Senior Vice President, Director of Value Transformation; and Linda Bolland, Senior Advisor, explain how in the Journal of Clinical Pathways.
To read the full article, click here
Gene therapies offer the promise of a one-and-done treatment for debilitating chronic disease—but payers still have lots of questions—from patient selection to duration of response. In this Clinical Leader article, Jeremy Schafer, PharmD, MBA, Senior Vice President of specialty solutions at Precision for Value, describes how well-designed clinical trials can answer these questions.
To read the full article, click here
In this article featured in the Journal of Clinical Pathways, Precision experts review both the financial and quality results of accountable care organizations (ACOs) and their implications for other payers.
In a featured article for PM360, Precision’s Ross Maclean and Phil Cyr identify three themes and eight interrelated factors which, if overlooked, can negatively impact a launch. In short, prescribers remain Very Important People in a launch, facing challenges around Vulnerability, Incentives, and Personalization.
In an article by Jeremy Schafer, learn why rare disease treatments are no longer safe from formulary exclusion lists and ways manufactures can lessen the risk of being on the list. (more…)
In an article for STAT, Ami Gopalan touches on CVS Health’s latest effort to nudge drug makers to reduce launch prices to a reasonable level. (more…)
The FDA and the US Department of Health and Human Services published final guidance on the presentation of health care economic information (HCEI) and preapproval information exchange (PIE). This is a new opportunity for manufacturers to engage with payers around cost-effectiveness. Precision’s Jeremy Schafer views it from the manufacturer’s perspective in his article for KNect365. (more…)
In response to the increase in value-focused care, vertical integration among payers and pharmacy benefit managers has increased as well, but what does this mean for manufacturers? (more…)